Abstract:The incidence of hepatocellular carcinoma(HCC) has increased worldwide over the past two decades.Surgical resection and liver transplantation have been demonstrated as potentially curative treatment options,which could be considered in 30% to 40% of HCC patients.Recent advancements of surgical treatment have focused not only on the surgical techniques,but also the hepatic functional reserve evaluation,resectability assessment and the effects of biological characteristics of tumor on prognosis.There is no single variable to evaluate hepatic functional reserve accurately.The combination of Child-Pugh classification,15-minute retention rate?for?Indocyanine Green(ICG15),portal vein pressure and remanent liver volume measurement is a reasonable strategy prior to Child-Pugh classification alone for liver resection.Five-year survival rate after liver resection for HCC is about 50%.The results may be acceptable for some selected patients underwent tumor resection with thrombectomy,including HCC with portal vein tumor thrombus and bile duct thrombosis.The choice of local resection or regular hepatectomy is still controversial although the former is common in HCC with cirrhosis,and the latter is in the setting without liver cirrhosis.The result of liver transplantation for HCC is better than that of liver resection,and Milan criteria is a generally accepted algorithm.Any attempts to expand the selection criteria should be cautious in the present setting of organ shortage.Salvage transplantation for intra-hepatic recurrence after liver resection may be a good choice in some resectable HCC.The recurrence and metastasis after surgical treatments are of the main obstacle to achieve better results.Identification of predictive factors could be helpful to develop prevention strategies.Due to the importance of biological characteristics in tumor recurrence and metastasis,a molecular classification to predict prognosis of HCC will lead to a more personalized medicine.Targeting key molecules of biological pathways could optimize therapeutic modality in HCC.

Systemic Therapy Alters the Landscape of Surgery in Hepatocellular Carcinoma： Opportunities and Challenges

[Advances in Perioperative Systemic Therapy for Hepatocellular Carcinoma].

[Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)]

[Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects]

Hepatocellular carcinoma: Advances in systemic therapies

Advancements in the Surgical Treatment of Hepatocellular Carcinoma

Opportunities and Challenges of Multidisciplinary Conversion Therapy in Advanced Hepatocellular Carcinoma

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review

Progress in Surgical Procedures of Hepatocellular Carcinoma

Conversion therapy strategies for hepatocellular carcinoma

Recent Update on Comprehensive Therapy for Advanced Hepatocellular Carcinoma

Recent Advances in Surgical Management Strategies for Hepatocellular Carcinoma

Research Advances in Systemic Therapy for Hepatocellular Carcinoma in the Era of Precision Medicine

Current Status of Multimodal & Combination Therapy for Hepatocellular Carcinoma.

Hepatocellular Carcinoma: Advances in Systemic Therapy

Conversion therapy for hepatocellular carcinoma: Strategies and methods

Conversion Therapy of Hepatocellular Carcinoma: Some Pivotal Issues to Be Resolved

Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma

Locoregional Combined with Systemic Therapies for Advanced Hepatocellular Carcinoma: an Inevitable Trend of Rapid Development

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Recent Progress in Treatment of Hepatocellular Carcinoma.